Clinical Significance of Thrombocytosis Before Preoperative Chemoradiotherapy in Rectal Cancer: Predicting Pathologic Tumor Response and Oncologic Outcome

Kim, Hye Jin; Choi, Gyu–Seog; Park, Jun Seok; Park, SooYeun; Kawai, Kazushige; Watanabe, Toshiaki

doi:10.1245/s10434-014-3988-8

Cited by 45 publications

(41 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Platelets play an integral role in the development and metastasis of cancer; high platelet counts have been linked to increased metastasis (Buergy et al, 2012) and poorer outcomes in multiple types of cancer (Kim et al, 2014, 2015; Moschini et al, 2014; Voutsadakis, 2014; Chadha et al, 2015; Ji et al, 2015). Tumor cells interact with platelets through a number of receptors and signaling molecules.…”

Section: Platelets and Cancer Progressionmentioning

confidence: 99%

Cancer and Thrombosis: The Platelet Perspective

Meikle

Kelly

Garg

et al. 2017

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Platelets are critical to hemostatic and immunological function, and are key players in cancer progression, metastasis, and cancer-related thrombosis. Platelets interact with immune cells to stimulate anti-tumor responses and can be activated by immune cells and tumor cells. Platelet activation can lead to complex interactions between platelets and tumor cells. Platelets facilitate cancer progression and metastasis by: (1) forming aggregates with tumor cells; (2) inducing tumor growth, epithelial-mesenchymal transition, and invasion; (3) shielding circulating tumor cells from immune surveillance and killing; (4) facilitating tethering and arrest of circulating tumor cells; and (5) promoting angiogenesis and tumor cell establishment at distant sites. Tumor cell-activated platelets also predispose cancer patients to thrombotic events. Tumor cells and tumor-derived microparticles lead to thrombosis by secreting procoagulant factors, resulting in platelet activation and clotting. Platelets play a critical role in cancer progression and thrombosis, and markers of platelet-tumor cell interaction are candidates as biomarkers for cancer progression and thrombosis risk.

show abstract

Section: Platelets and Cancer Progressionmentioning

confidence: 99%

Cancer and Thrombosis: The Platelet Perspective

Meikle

Kelly

Garg

et al. 2017

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…A total of 20 studies (7,(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) that met the inclusion criteria were retrieved for analysis in the present study. The selection process of the included studies is presented in Fig.…”

Section: Identification Of Eligible Studiesmentioning

confidence: 99%

The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis

Zhang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Previous studies have linked the presence of thrombocytosis with the progression and development of cancer; however, this trend requires further investigation. The present study aimed to derive an estimation of the degree of association between thrombocytosis and the 5-year overall survival rate of patients with cancer, as well as common clinicopathological features, by performing a meta-analysis of 20 (n=12,778) published studies. The PubMed and Embase databases were searched systematically for all relevant articles published in English. Odds ratios (ORs) with 95% confidence intervals (CI) were calculated using a fixed effects or random effects model to evaluate the degree of the observed associations. The results suggested that thrombocytosis (platelet count, >400x10 9 /l) correlated with a decreased 5-year overall survival rate (OR=2.70, 95% CI=2.03-3.61) and an advanced tumor-node-metastasis stage (III + IV; OR=2.14, 95% CI=1.58-2.90). Furthermore, these associations remained robust following stratification of the data by cancer type and ethnicity. In addition, thrombocytosis (platelet count, >300x10 9 /l) correlated with a decreased 5-year overall survival rate in patients with colorectal cancer (OR=3.49, 95% CI=1. 44-8.46). Although certain biases were not able to be eliminated, the present meta-analysis suggested that thrombocytosis is a valuable indicator for the evaluation of pathological diagnosis and prognosis for patients with cancer. Further studies are required to investigate the effect of thrombocytosis on the prognosis of patients with cancer. IntroductionDespite improvements in early diagnosis, radical surgery and various novel treatments, the prognosis for patients with cancer remains poor (1). Esophageal cancer patients without detectable metastasis in the clinic at the time of diagnosis may still succumb to cancer recurrence following surgery (2). This suggests that certain metastasis of cancer may not be detected using conventional biochemistry testing, imaging or histopathological methods (2). Therefore, a novel biological marker that may enhance the ability to accurately predict patient treatment outcomes is required. In previous years, a number of studies have investigated potential prognostic factors in patients with cancer. Previous studies have demonstrated that certain preoperative alterations in hematological parameters may be associated with patient outcomes for several forms of solid tumors (3). In addition, it has been suggested that circulating platelet (PLT)-tumor cell aggregates may promote cancer metastasis (4).Previous studies have investigated the association between thrombocytosis and tumor growth and development in various forms of malignancy (5-7); however, this trend requires further investigation. Yu et al (8) demonstrated, using a meta-analysis, that thrombocytosis (PLT count >400x10 9 /l) may be associated with a poorer prognosis for patients with a gynecological malignancy. Therefore, the present meta-analysis was performed in order to assess the associati...

show abstract

“…Different cutoff level for CEA was found to be significant for prediction of pCR in several studies. Most studies proposed 5 ng/ml [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] and others 2.5 ng/ml [9,28], 3 ng/ml [29,30], 3.5 ng/ml [31,32] or 6 ng/ml [22]. Therefore, elevated CEA level was defined as ≥ 5 ng/ml, and normal CEA level refers to <5 ng/ml in current study.…”

Section: Data Extraction and Definitionsmentioning

confidence: 99%

“…As indicated in the search flow diagram (Figure 1), 14 studies [13][14][15][16][18][19][20][21][22][23][25][26][27] published from 2006 to 2015 fulfilled the inclusion criteria and were finally included in the meta-analysis. The characteristics of included studies are summarized in Table 1.…”

Section: Description Of Eligible Studiesmentioning

confidence: 99%

Pretreatment Serum Cea as a Predictive Biomarker for the Response to Neoadjuvant Chemoradiotherapy: A Meta-Analysis in Rectal Cancer

Yu¹,

Chen²,

Cai³

2015

J Carcinog Mutagen

View full text Add to dashboard Cite

show abstract

Clinical Significance of Thrombocytosis Before Preoperative Chemoradiotherapy in Rectal Cancer: Predicting Pathologic Tumor Response and Oncologic Outcome

Abstract: Thrombocytosis is a negative predictive factor for a pCR and has an adverse impact on survival in rectal cancer. The predictive value of this easily available clinical factor should not be underestimated, and better therapeutic strategies for these tumors are required.

Cited by 45 publications

References 27 publications

Cancer and Thrombosis: The Platelet Perspective

Cancer and Thrombosis: The Platelet Perspective

The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis

Pretreatment Serum Cea as a Predictive Biomarker for the Response to Neoadjuvant Chemoradiotherapy: A Meta-Analysis in Rectal Cancer

Contact Info

Product

Resources

About